In vivo Patient-Derived Xenograft (PDX) Models for Oncology Research Studies скачать в хорошем качестве

In vivo Patient-Derived Xenograft (PDX) Models for Oncology Research Studies

Dr. Julia Schueler, Research Director, Discovery Services at Charles River, explains in vivo patient-derived xenograft (PDX) models. PDX models of cancer are created by implanting tissues or cells from a patient’s tumor into an immunodeficient mouse. The main advantages of PDX models are that they maintain their genetic heterogeneity as well as the histological makeup of the patient and preserve them over the passages. This gives them the possibility to cover all different histotypes from a specific disease, making them useful for drug development and tumor biology research. Charles River offers a great PDX collection covering more than 500 different models, ranging from broad models (e.g., non-small cell lung cancer, breast cancer and colon cancer) to tumor models with a high medical need (e.g., ovarian cancer, acute myeloid leukemia, non-Hodgkin lymphoma and prostate cancer). Our PDX models are characterized with molecular techniques like whole-exome sequencing and RNA-seq. We also have patient metadata available as well as histology and immunohistochemistry data and sensitivity towards standard of care treatments. For more related PDX Resources: • Patient-Derived Xenografts – PDX Models Web Page: http://bit.ly/2S0oNpV • “Humanized Mouse Models: PDX and Traditional Xenografts” Webinar Replay: http://bit.ly/2tArWDy • Patient-Derived Tumor Xenograft (PDX) Models for Oncology Research Technical Sheet: http://bit.ly/2Up4K6d